Influence of the Neuromuscular Blockade on Mask Ventilation
Information source: University of Rostock
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Complication of Ventilation Therapy; Observation of Neuromuscular Block
Intervention: Rocuronium 0.3 mg/kg (Drug); Rocuronium 0.6 mg/kg (Drug); Rocuronium 0.9 mg/kg (Drug); Placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Rostock Official(s) and/or principal investigator(s):
Thomas Mencke, Prof., Principal Investigator, Affiliation: University of Rostock
Overall contact:
Thomas Mencke, Prof., Phone: +49 381 494 6411, Email: thomas.mencke@googlemail.com
Summary
Mask ventilation during induction of anesthesia can be improved by administration of
neuromuscular blocking agents (NMBAs). NMBAs are usually administered after testing mask
ventilation; however, muscle relaxants may improve mask ventilation and they do not alter
mask ventilation. Thus, growing evidence suggests to administer muscle relaxants before
testing mask ventilation. We will study different dosages of rocuronium; we assume that
higher dosages of rocuronium will improve mask ventilation compared with lower dosages.
Clinical Details
Official title: The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Incidence of improved mask ventilation after rocuronium administration
Detailed description:
Mask ventilation during induction of anesthesia can be improved by administration of
neuromuscular blocking agents (NMBAs). NMBAs are usually administered after testing mask
ventilation; however, muscle relaxants may improve mask ventilation and they do not alter
mask ventilation. Thus, growing evidence suggests to administer muscle relaxants before
testing mask ventilation. We will administer rocuronium 0. 3 mg/kg, 0. 6 mg/kg, 0. 9 mg/kg and
saline (placebo group) before starting with mask ventilation. We will grade mask ventilation
based on various scores before and after rocuronium application. Afterwards patient`s
tracheas will be intubated. We assess risk factors for difficult mask ventilation.
We hypothesize that rocuronium 0. 9 mg/kg will be superior to rocuronium 0. 3 mg/kg and
saline.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients with ASA I-III
- required tracheal intubation
- informed consent
Exclusion Criteria:
- known allergy against anesthetics
- known difficult airway
Locations and Contacts
Thomas Mencke, Prof., Phone: +49 381 494 6411, Email: thomas.mencke@googlemail.com
Department of Anesthesia and Intensive Care Medicine, University of Rostock, Rostock, Mecklenburg/Vorpommern 18057, Germany; Recruiting
Thomas Mencke
Michael Hellmund
Michael Hellmund, Principal Investigator
Additional Information
Starting date: March 2015
Last updated: March 27, 2015
|
